Evaluation of an interactive web-based programme on relapse management for people with multiple sclerosis (POWER@MS2): study protocol for a process evaluation accompanying a randomised controlled trial

Lisa Wenzel, Christoph Heesen, Jutta Scheiderbauer, Markus van de Loo, Sascha Köpke, Anne Christin Rahn, Lisa Wenzel, Christoph Heesen, Jutta Scheiderbauer, Markus van de Loo, Sascha Köpke, Anne Christin Rahn

Abstract

Introduction: Process evaluations accompanying complex interventions examine the implementation process of the underlying intervention, identify mechanisms of impact and assess contextual factors. This paper presents the protocol for a process evaluation conducted alongside the randomised controlled trial POWER@MS2. The trial comprises the evaluation of a web-based complex intervention on relapse management in 188 people with multiple sclerosis conducted in 20 centres. The web-based intervention programme focuses on relapse treatment decision making and includes a decision aid, a nurse-led webinar and an online chat. With the process evaluation presented here, we aim to assess participants' responses to and interactions with the intervention to understand how and why the intervention produces change.

Methods and analysis: A mixed methods design is used to explore the acceptance of the intervention as well as its use and impact on participants. Participants are people with multiple sclerosis, neurologists, nurses and stakeholders. Quantitative semistandardised evaluation forms will be collected throughout the study. Qualitative semistructured telephone interviews will be conducted at the end of the study with selected participants, especially people with multiple sclerosis and neurologists. Quantitative data will be collected and analysed descriptively. Based on the results, the qualitative interviews will be conducted and analysed thematically, and the results will be merged in a joint display table.

Ethics and dissemination: The process evaluation has received ethical approval from the Ethical Committee of the University of Lübeck (reference 19-024). Findings will be disseminated in peer-reviewed journals, at conferences, meetings and on relevant patient websites.

Trial registration number: NCT04233970.

Keywords: medical education & training; multiple sclerosis; world wide web technology.

Conflict of interest statement

Competing interests: CH has received research grants from Celgene, Genzyme, Roche and Merck.

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Figures

Figure 1
Figure 1
POWER@MS2 study flow. Reproduced with permission from Rahn et al.
Figure 2
Figure 2
Research questions and assessment methods adopted for the process evaluation of POWER@MS2 (adapted from Moore et al)
Figure 3
Figure 3
The explanatory sequential research design in POWER@MS2 (adapted from Creswell and Plano Clark). RCT, randomised controlled trial.

References

    1. World Health Organisation . Atlas multiple sclerosis resources in the world 2008. Geneva: WHO Press, 2008.
    1. Holstiege J, Steffen A, Goffrier B, et al. . Epidemiologie der Multiplen Sklerose-eine populationsbasierte deutschlandweite Studie. Zentralinstitut für die kassenärztliche Versorgung Deutschl, 2017. Available: [Accessed 22 Apr 2020].
    1. Petersen G, Wittmann R, Arndt V, et al. . Epidemiologie der Multiplen Sklerose in Deutschland. Regionale Unterschiede und Versorgungsstruktur in Abrechnungsdaten der gesetzlichen Krankenversicherung. Nervenarzt 2014;85:990–8.
    1. Flachenecker P, Sklerose M. Update zu Diagnostik und therapie. Neuroreha 2019;2019:149–54.
    1. Lavery AM, Verhey LH, Waldman AT. Outcome measures in relapsing-remitting multiple sclerosis: capturing disability and disease progression in clinical trials. Mult Scler Int 2014;2014:1–13. 10.1155/2014/262350
    1. Kip M, Zimmermann A. Krankheitsbild Multiple Sklerose. In: Kip M, Schönfelder T, Bleß H-H, eds. Weißbuch multiple Sklerose. Versorgungssituation in Deutschland. Berlin, Heidelberg: Springer, 2016: 1–12.
    1. Schönfelder T, Pöhlau D. Früherkennung und Diagnostik der Multiplen Sklerose. In: Kip M, Schönfelder T, Bleß H-H, eds. Weißbuch multiple Sklerose. Versorgungssituation in Deutschland. Berlin, Heidelberg: Springer, 2016: 23–54.
    1. Kip M, Wiendl H. Therapie der Multiplen Sklerose. Stufentherapie. In: Kip M, Schönfelder T, Bleß H-H, eds. Weißbuch multiple Sklerose. Versorgungssituation in Deutschland. Berlin, Heidelberg: Springer, 2016: 56–74.
    1. Kompetenznetz Multiple Sklerose . S2k-Leitlinie diagnose und therapie Der Multiplen Sklerose, neuromyelitis optica Spektrum und MOG-IgGassoziierte Erkrankungen, 2020. Available: [Accessed 10 Nov 2020].
    1. Citterio A, La Mantia L, Ciucci G, et al. . Corticosteroids or ACTH for acute exacerbations in multiple sclerosis. Cochrane Database Syst Rev 2000;7. 10.1002/14651858.CD001331
    1. Gal RL, Vedula SS, Beck R, et al. . Corticosteroids for treating optic neuritis. Cochrane Database Syst Rev 2015;74. 10.1002/14651858.CD001430.pub4
    1. Köpke S, Heesen C, Kasper J, et al. . Steroid treatment for relapses in multiple sclerosis - the evidence urges shared decision-making. Acta Neurol Scand 2004;110:1–5. 10.1111/j.1600-0404.2004.00284.x
    1. Rieckmann P, Bassetti C, Beer K. Immunmodulatorische Stufentherapie der Multiplen Sklerose: Neue Aspekte und praktische Umsetzung, März 2002. Nervenarzt 2002;73:556–63.
    1. National Clinical Guideline Centre (UK) . Multiple sclerosis: management of multiple sclerosis in primary and secondary care. London: National Institute for Health and Care Excellence (UK), 2014. Available: [Accessed 30 Apr 2020].
    1. Burton JM, O’Connor PW, Hohol M. Oral versus intravenous steroids for treatment of relapses in multiple sclerosis. Cochrane Database Syst Rev 2009;8. 10.1002/14651858.CD006921
    1. Lattanzi S, Cagnetti C, Danni M, et al. . Oral and intravenous steroids for multiple sclerosis relapse: a systematic review and meta-analysis. J Neurol 2017;264:1697–704. 10.1007/s00415-017-8505-0
    1. Ramo-Tello C, Grau-López L, Tintoré M, et al. . A randomized clinical trial of oral versus intravenous methylprednisolone for relapse of MS. Mult Scler 2014;20:717–25. 10.1177/1352458513508835
    1. Rahn AC, Wenzel L, Icks A. Development and evaluation of an interactive web-based decision-making programme on relapse management for people with multiple sclerosis (POWER@MS2)—study protocol for a randomised controlled trial. Trials 2021;22. 10.1186/s13063-021-05059-1
    1. Moore G, Audrey S, Barker M, et al. . Process evaluation of complex interventions: medical Research Council guidance. London: MRC Population Health Science Research Network, 2014.
    1. Moore GF, Audrey S, Barker M, et al. . Process evaluation of complex interventions: medical Research Council guidance. BMJ 2015;350:h1258. 10.1136/bmj.h1258
    1. Linnan L, Steckler A. Process Evaluation for Public Health Interventions and Research: An Overview. In: Steckler A, Linnan L, eds. Process evaluation for public health interventions and research. San Fransisco, CA: Jossey-Bass, 2002: 1–23.
    1. Moore G, Audrey S, Barker M, et al. . Process evaluation in complex public health intervention studies: the need for guidance. J Epidemiol Community Health 2014;68:101–2. 10.1136/jech-2013-202869
    1. Johnson RB, Onwuegbuzie AJ, Turner LA. Toward a definition of mixed methods research. J Mix Methods Res 2007;1:112–33. 10.1177/1558689806298224
    1. Bravo P, Edwards A, Barr PJ, et al. . Conceptualising patient empowerment: a mixed methods study. BMC Health Serv Res 2015;15:252. 10.1186/s12913-015-0907-z
    1. Ajzen I. The theory of planned behaviour: reactions and reflections. Psychol Health 2011;26:1113–27. 10.1080/08870446.2011.613995
    1. Lühnen J, Albrecht M, Mühlhauser I, et al. . Leitlinie evidenzbasierte Gesundheitsinformation. Evidenzbasierte Leitlinie, 2017. Available: [Accessed 23 Jun 2020].
    1. Sackett DL, Rosenberg WM, Gray JA, et al. . Evidence based medicine: what it is and what it isn't. BMJ 1996;312:71–2. 10.1136/bmj.312.7023.71
    1. Craig P, Dieppe P, Macintyre S, et al. . Developing and evaluating complex interventions: the new medical Research Council guidance. BMJ 2008;337:a1655. 10.1136/bmj.a1655
    1. Grant A, Treweek S, Dreischulte T, et al. . Process evaluations for cluster-randomised trials of complex interventions: a proposed framework for design and reporting. Trials 2013;14:15. 10.1186/1745-6215-14-15
    1. Creswell JW, Plano Clark VL. Designing and conducting mixed methods research. 2nd ed. Thousand Oaks, California: SAGE, 2011.
    1. Rahn AC, Köpke S, Kasper J, et al. . Evaluator-blinded trial evaluating nurse-led immunotherapy decision coaching in persons with relapsing-remitting multiple sclerosis (DECIMS) and accompanying process evaluation: study protocol for a cluster randomised controlled trial. Trials 2015;16:106. 10.1186/s13063-015-0611-7
    1. Frohman EM, Shah A, Eggenberger E, et al. . Corticosteroids for multiple sclerosis: I. Application for treating exacerbations. Neurotherapeutics 2007;4:618–26. 10.1016/j.nurt.2007.07.008
    1. Braun V, Clarke V. What can “thematic analysis” offer health and wellbeing researchers? Int J Qual Stud Health Well-being 2014;9:26152. 10.3402/qhw.v9.26152
    1. Köpke S, Richter T, Kasper J, et al. . Implementation of a patient education program on multiple sclerosis relapse management. Patient Educ Couns 2012;86:91–7. 10.1016/j.pec.2011.03.013

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera